US initial public offerings by biotechnology companies in 2015 dried up in November, but since Editas Medicine Inc. and BeiGene Ltd. had strong offerings to kick off February, does that mean that dozens of drug developers will be able to go public again in 2016?
Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?
US initial public offerings by biotechnology companies in 2015 dried up in November, but since Editas Medicine Inc. and BeiGene Ltd. had strong offerings to kick off February, does that mean that dozens of drug developers will be able to go public again in 2016?
More from Archive
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.